Corrigendum: Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)

Front Neurosci. 2023 Jul 31:17:1237920. doi: 10.3389/fnins.2023.1237920. eCollection 2023.

Thanh G Phan^{1

2}, Rebecca Lim^{3

4}, Mirja Krause^{3

4}, Siow T Chan^{3

4}, Hannah McDonald^{3

4}, Poh-Yi Gan^{5

6}, Shenpeng R Zhang⁷, Liz J Barreto Arce⁷, Jason Vuong^{1

2}, Tharani Thirugnanachandran^{1

2}, Benjamin Clissold^{1

2}, John Ly^{1

2}, Shaloo Singhal^{1

2}, Marie Veronic Hervet^{1

2}, Hyun Ah Kim⁷, Grant R Drummond⁷, Euan M Wallace^{4

8}, Henry Ma^{1

2}, Christopher G Sobey⁷

¹ Clinical Trials, Imaging and Informatics Division, Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
² Department of Neurology, Monash Health, Clayton, VIC, Australia.
³ The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
⁴ Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia.
⁵ Department of Medicine, Centre for Inflammatory Diseases, Monash Medical Centre, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
⁶ Department of Immunology, Monash Health, Monash Medical Centre, Clayton, VIC, Australia.
⁷ Department of Microbiology, Anatomy, Physiology and Pharmacology, Centre for Cardiovascular Biology and Disease Research, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, VIC, Australia.
⁸ Victorian Department of Health, Melbourne, VIC, Australia.

Abstract

[This corrects the article DOI: 10.3389/fnins.2023.1153231.].

Keywords: allogeneic; clinical trial; ischemic stroke; phase I; stem cell.